Nomogram for Estimating Overall Survival in Patients With Metastatic Pancreatic Cancer


This analysis investigated nomogram use to evaluate metastatic pancreatic cancer prognosis.


Thirty-four baseline factors were examined in the Metastatic Pancreatic Adenocarcinoma Clinical Trial (MPACT) (nab-paclitaxel plus gemcitabine vs gemcitabine) data set. Factors significantly (P < 0.1) associated with overall survival (OS) in a univariable model or with known clinical relevance were tested further. In a multivariable model, factors associated with OS (P < 0.1) were selected to generate the primary nomogram, which was internally validated using bootstrapping, a concordance index, and calibration plots.


Using data from 861 patients, 6 factors were retained (multivariable analysis): neutrophil-lymphocyte ratio, albumin level, Karnofsky performance status, sum of longest diameter of target lesions, presence of liver metastases, and previous Whipple procedure. The nomogram distinguished low-, medium-, and high-risk groups (concordance index, 0.67; 95% confidence interval, 0.65-0.69; median OS, 11.7, 8.0, and 3.3 months, respectively).


This nomogram may guide estimates of the range of OS outcomes and contribute to patient stratification in future prospective metastatic pancreatic cancer trials; however, external validation is required to improve estimate reliability and applicability to a general patient population. Caution should be exercised in interpreting these results for treatment decisions: patient characteristics could differ from those included in the nomogram development.

AuthorsD Goldstein, DD Von Hoff, EG Chiorean, M Reni, J Tabernero, RK Ramanathan, M Botteman, A Aly, S Margunato-Debay, B Lu, CU Louis, D McGovern, C Khoon Lee
Therapeutic AreaOncology
Service AreaModeling & Meta-Analysis
LinkClick Here

Share this post